

Ignacio Garrido-Laguna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8269842/publications.pdf>

Version: 2024-02-01

121
papers

7,479
citations

182225

30
h-index

64407

83
g-index

121
all docs

121
docs citations

121
times ranked

13004
citing authors

#	ARTICLE	IF	CITATIONS
1	The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 492-500.	0.6	3
2	A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 39-39.	0.8	1
3	Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 268-275.	2.3	3
4	Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 144-150.	2.3	4
5	Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.		6
6	Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 663-675.	0.7	8
7	The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 291-291.	0.8	2
8	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
9	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.	0.7	9
10	Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 796-802.	0.5	1
11	Emerging Treatment Strategies in Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 773-787.	0.5	3
12	A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. <i>Oncologist</i> , 2021, 26, e1844-e1853.	1.9	18
13	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	3.2	22
14	Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. <i>Neoplasia</i> , 2021, 23, 859-869.	2.3	6
15	Therapeutic Targeting of Autophagy in Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 709-718.	0.6	4
16	Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110458.	1.4	7
17	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 478-482.	2.3	21
18	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	5.1	1,034

#	ARTICLE	IF	CITATIONS
19	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	12.5	244
20	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
21	Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. <i>Cell Reports</i> , 2020, 32, 107994.	2.9	15
22	Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3217-3230.	0.8	151
23	O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). <i>Annals of Oncology</i> , 2020, 31, 232-233.	0.6	14
24	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€œDeficient Pancreatic Cancer After Planned Treatment Interruption. <i>JCO Precision Oncology</i> , 2020, 4, 780-784.	1.5	2
25	The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. <i>PLoS ONE</i> , 2020, 15, e0229063.	1.1	6
26	The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. <i>Cancer Medicine</i> , 2020, 9, 1703-1711.	1.3	12
27	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 806-815.	2.3	310
28	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 137-139.	0.6	0
29	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019, 24, 219-228.	1.9	30
30	Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). <i>Annals of Oncology</i> , 2019, 30, iv134.	0.6	7
31	Prognostic Factors Affecting Overall Survival in Non-metastatic, Primary Squamous Cell Carcinoma of the Pancreas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, E31-E32.	0.4	0
32	Firstâ€œinâ€œhuman, phase I study of PFâ€œ06647263, an antiâ€œFNA4 calicheamicin antibodyâ€œ drug conjugate, in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 1798-1808.	2.3	34
33	Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. <i>ESMO Open</i> , 2019, 4, e000539.	2.0	3
34	Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 355-362.	0.6	30
35	Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for firstâ€œline treatment of metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2019, 37, 482-489.	1.2	17
36	Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1401-1413.	0.9	7

#	ARTICLE	IF	CITATIONS
37	A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 330-330.	0.8	1
38	Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab.. Journal of Clinical Oncology, 2019, 37, 69-69.	0.8	1
39	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1109-1133.	2.3	92
40	The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 419-419.	0.8	1
41	Cancer Immunotherapy in the Immunosuppressed Patients and Its Relevance to Clinical Practice. Journal of Immunotherapy and Precision Oncology, 2019, 2, 127-128.	0.6	1
42	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369.	2.3	675
43	Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 2018, 3, e000282.	2.0	21
44	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncology, 2018, 14, 947-962.	1.1	9
45	Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2545-2556.	0.8	204
46	Combination immunotherapy and radiation therapy strategies for pancreatic cancer targeting multiple steps in the cancer immunity cycle. Journal of Gastrointestinal Oncology, 2018, 9, 1014-1026.	0.6	42
47	Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology, 2018, 2, 1-7.	1.5	32
48	Large database utilization in health outcomes research in pancreatic cancer: an update. Journal of Gastrointestinal Oncology, 2018, 9, 996-1004.	0.6	8
49	TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunology, Immunotherapy, 2018, 67, 1659-1667.	2.0	152
50	(OA44) Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. International Journal of Radiation Oncology Biology Physics, 2018, 101, e18-e19.	0.4	2
51	Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 2018, 3, e000386.	2.0	11
52	Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer. Cancer Research, 2018, 78, CT124-CT124.	0.4	18
53	Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.. Journal of Clinical Oncology, 2018, 36, 4015-4015.	0.8	34
54	Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy.. Journal of Clinical Oncology, 2018, 36, 404-404.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions.. Journal of Clinical Oncology, 2018, 36, 521-521.	0.8	27
56	The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 111-111.	0.8	0
57	A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS524-TPS524.	0.8	0
58	Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer.. Journal of Clinical Oncology, 2018, 36, 97-97.	0.8	0
59	Pembrolizumab in Advanced Gastrointestinal Malignancies with Defective DNA Mismatch Repair: A Case Series. Journal of Immunotherapy and Precision Oncology, 2018, 1, 1-6.	0.6	0
60	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 2017, 123, 3816-3824.	2.0	35
61	Multi-agent Induction Chemotherapy Followed by Chemoradiation is Associated With Improved Survival Compared to Chemotherapy Alone in Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E193-E194.	0.4	0
62	Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2017, 24, 4001-4008.	0.7	20
63	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 2017, 9, 797-804.	1.0	30
64	Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 175-182.	1.0	2
65	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, 2017, 17, 646.	1.1	24
66	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2017, 8, 387-404.	0.6	21
67	A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 2511-2511.	0.8	6
68	Pembrolizumab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.. Journal of Clinical Oncology, 2017, 35, 792-792.	0.8	2
69	A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG Case Reports Journal, 2017, 4, e34.	0.2	3
70	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy, 2016, 9, 75.	1.0	5
71	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547.	1.9	63
72	Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clinical Neurology and Neurosurgery, 2016, 149, 11-14.	0.6	2

#	ARTICLE	IF	CITATIONS
73	A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. <i>Annals of Oncology</i> , 2016, 27, vi367.	0.6	0
74	Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3020-3020.	0.8	21
75	Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 452-452.	0.8	14
76	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016, 7, 67521-67531.	0.8	44
77	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
78	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2520-2520.	0.8	4
79	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. <i>Oncoscience</i> , 2015, 2, 285-293.	0.9	4
80	Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 687-687.	0.8	0
81	Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 311-311.	0.8	0
82	Amplification of CRKL in human cancer: A rare event associated with potential sensitivity to targeted therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1526-1526.	0.8	0
83	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2584-2584.	0.8	0
84	Abstract B93: A data base of N of 1 case reports from pancreatic cancer patients enrolled in First-in-man studies 2002 through 2012. , 2015, , .		0
85	Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma. , 2015, , .		0
86	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. <i>Discovery Medicine</i> , 2015, 19, 101-8.	0.5	0
87	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. <i>Discovery Medicine</i> , 2015, 19, 109-16.	0.5	13
88	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. <i>Cancer</i> , 2014, 120, 2164-2173.	2.0	27
89	Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-Based Study in Utah. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2078-2084.e2.	2.4	42
90	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2517-2517.	0.8	10

#	ARTICLE	IF	CITATIONS
91	A framework for genomic biomarker actionability and its use in clinical decision making. <i>Oncoscience</i> , 2014, 1, 614-623.	0.9	26
92	Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4596-TPS4596.	0.8	0
93	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. <i>Discovery Medicine</i> , 2014, 18, 323-30.	0.5	6
94	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. <i>Discovery Medicine</i> , 2014, 18, 331-9.	0.5	8
95	A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 1257-1264.	1.2	59
96	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. <i>Blood</i> , 2013, 122, 3048-3048.	0.6	1
97	Ridaforolimus in Advanced Sarcomas: A Leap Forward or Missed Opportunity?. <i>Journal of Clinical Oncology</i> , 2012, 30, 892-893.	0.8	2
98	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. <i>Clinical Colorectal Cancer</i> , 2012, 11, 297-303.	1.0	6
99	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	0.8	414
100	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012, 118, 1422-1428.	2.0	88
101	KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. <i>PLoS ONE</i> , 2012, 7, e38033.	1.1	44
102	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. <i>Oncotarget</i> , 2012, 3, 1566-1575.	0.8	79
103	Outcomes of Patients with Advanced Non-small Cell Lung Cancer Treated in a Phase I Clinic. <i>Oncologist</i> , 2011, 16, 327-335.	1.9	8
104	The inverted pyramid of biomarker-driven trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 562-566.	12.5	17
105	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2011, 6, e22769.	1.1	174
106	Novel Therapeutic Targets in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1601-1612.	0.5	127
107	<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 558-565.	1.9	311
108	Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5793-5800.	3.2	204

#	ARTICLE	IF	CITATIONS
109	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. <i>Cancer Biology and Therapy</i> , 2011, 12, 598-609.	1.5	103
110	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1311-1316.	1.9	354
111	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 3-8.	1.9	238
112	Abstract 2264: K-ras mutations in colorectal cancer may predict a pattern of organ-specific metastasis. , 2011, , .		0
113	Abstract 1279: Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. , 2011, , .		0
114	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. <i>British Journal of Cancer</i> , 2010, 103, 649-655.	2.9	65
115	Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes. <i>Journal of Clinical Oncology</i> , 2010, 28, e633-e636.	0.8	77
116	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 4031-4037.	3.2	15
117	Abstract 2773: Clinical outcomes of patients with head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. , 2010, , .		0
118	Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 183-185.	1.2	2
119	New scaffolds for the design of selective estrogen receptor modulators. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3486.	1.5	24
120	MRI Evaluation of Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 191-193.	13.9	2
121	Is There Any Reason to Delay Introduction of Tumor Necrosis Factor in the Management of In-Transit Metastasis of Unresectable Melanoma?. <i>Journal of Clinical Oncology</i> , 2007, 25, 1149-1149.	0.8	4